R&D channel feed – Endpoints News

R&D channel feed

Learning from past mistakes, Centrexion clears a big PhIIb hurdle for its pain drug

9 years ago

Big Pharma’s woeful numbers on drug R&D just got even worse

9 years ago

Gates-backed Exicure wraps 2016 with its first major collaboration and a plan for the year ahead

9 years ago

Achaogen slowly soars, speeding top antibiotic to FDA/EMA after PhIII scores positive results

9 years ago

Novartis-allied Ophthotech blitzed after a pair of PhIII disasters for wet-AMD franchise drug

9 years ago

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

9 years ago

Moving on past sola wreckage, Lilly doubles down on one more Alzheimer’s drug from AstraZeneca

9 years ago

Eli Lilly conducts an autopsy of an Alzheimer’s megaflop

9 years ago

Biogen spells out remarkable efficacy data in Alzheimer's for aducanumab, but safety threat persists

9 years ago

Horizon Pharma folds its cards on Friedreich’s Ataxia after Actimmune flunks PhIII

9 years ago

Voyager shares spike on an early glimpse of promise for Parkinson’s gene therapy

9 years ago

J&J is forced to suspend recruitment in PhI diabetes study, raising questions about another Hanmi drug

9 years ago

AbbVie’s PARP inhibitor flounders in PhII as rivals surge ahead in late-stage drive

9 years ago

With new name, new CEO, Cascadian now rolls out a new pivotal plan for lead cancer drug

9 years ago

The FDA just signed off on a Formula 1 pivotal track for Sage's postpartum depression drug

9 years ago

In a rare blockbuster performance for AstraZeneca, Tagrisso comes through on lung cancer PhIII

9 years ago

Juno gets some badly needed relief after a glimpse of upbeat early data on JCAR017

9 years ago

Cerecor blasted as its second clinical roll of the dice in days comes up snake eyes

9 years ago

Rattled by immune responses, Spark will pay $30M-plus to get Selecta’s help in ending threat

9 years ago

ReNeuron’s stem cell treatment fails a small stroke study, but the biotech says it’s ready for pivotal

9 years ago

Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission

9 years ago

What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis

9 years ago

#ASH16: Pfizer offers a thumbs-up on OS data from PhII blood cancer study of glasdegib

9 years ago

In wake of a CAR-T restructuring, Novartis says it’s ready to hunt a pioneering OK for lead program

9 years ago

First page Previous page 309 310 311312313 314 315 Next page Last page